TYTomohiro Yamaguchi

Tomohiro Yamaguchi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tomohiro Yamaguchi has a total of 307 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Exploratory Analysis of Factors Associated With the Recovery of Erectile Dysfunction After Rectal Cancer Surgery (Sub‐Analysis of LANDMARC Trial)

    by Ryosuke Mizuno, Koya Hida, Masakatsu Numata, Takashi Sakamoto, Kazutaka Obama, Akio Shiomi, Ryo Inada, Manabu Shiozawa, Mayumi Ozawa, Masanori Hotchi, et al.

    Background: Erectile dysfunction (ErD) is an important complication after rectal cancer surgery, however a substantial proportion of patients experience functional recovery over time. Evidence regarding which patients are more likely to recover remains limited. This study aimed to identify factors associated with the recovery of postoperative ErD in male patients undergoing minimally invasive rectal cancer surgery. Methods: This study was a sub‐analysis of the LANDMARC study, a multicenter prospective trial across 49 hospitals, including male patients who underwent minimally invasive surgery for middle or lower rectal cancer. Erectile function was assessed preoperatively and up to 12 months postoperatively using the Erection Hardness Score (EHS). Analyses focused on ErD at 3 months and recovery at 12 months postoperatively. Modified Poisson regression was used to explore factors associated with recovery. Results: Among 337 patients with complete data, postoperative ErD was observed in 136 patients (40%). Of these, 67 patients (49%) showed recovery of ErD at 12 months. Factors associated with the recovery of ErD were upper tumor location (RR: 1.51; 95% CI: 1.06, 2.16), pathological T stage ≤ 2 (RR: 1.59; 95% CI: 1.07, 2.38), absence of neoadjuvant chemotherapy (RR: 2.05; 95% CI: 1.01, 4.13), and creation of a diverting stoma (RR: 1.85; 95% CI: 1.21, 2.85). Sensitivity analyses using alternative recovery definitions showed consistent results, particularly for tumor location and diverting stoma. Conclusions: ErD after rectal cancer surgery is not always irreversible. These exploratory findings may help inform future studies aimed at developing individualized penile rehabilitation strategies after rectal cancer surgery.

  • Open Access

    First Annual Report for Robot‐Assisted Surgery Based on the National Clinical Database 2019 in Japan: Report on Three Major Gastrointestinal Fields

    by Ichiro Takemasa, Hiroyuki Yamamoto, Tatsuto Nishigori, Takeo Fujita, Tomoki Makino, Yusuke Taniyama, Masanori Terashima, Masanori Tokunaga, Takatoshi Matsuyama, Tomohiro Yamaguchi, et al.

    Aim: The adoption of robot‐assisted surgery (RAS) in Japan has progressed significantly since its initial approval in 2009. RAS gradually expanded into various surgical fields with 35 procedures now covered under Japan's national health insurance. This study provides an inaugural assessment of RAS outcomes for seven digestive procedures introduced in 2018. Methods: The Japanese Society for Endoscopic Surgery working group established an RAS registry integrating data from the National Clinical Database and additional RAS‐specific records. The analysis focused on three major gastrointestinal fields: the esophagus, stomach, and rectum. Results: In 2019, 530 esophagectomies, 2295 gastrectomies, and 3269 proctectomies were performed. RAS for these procedures was characterized by relatively long operative times, low intraoperative blood loss, and very low conversion rates to open surgery (< 1%). Postoperative morbidity rates Grade IIIa or higher were 23.2% for esophagectomy, 4.9% for gastrectomy, and 9.4% for proctectomy. Length of postoperative hospital stay correlated with morbidity, though readmission (1.3%–3.1%) and postoperative mortality rates (0.3%–0.6%) remained low. The early nationwide implementation of RAS in Japan was marked by a high surgeon qualification rate (98.9%) and meticulous case selection; the DVSS Xi model accounted for 66.3% of robotic platforms used. Conclusion: These findings underscore the need for ongoing surveillance and data‐driven evaluation to ensure safe and effective implementation of RAS. Future longitudinal analyses will refine surgical quality, optimize resource allocation, and advance minimally invasive techniques. This study highlights the transformative potential of RAS in Japanese surgical practice and its alignment with global trends.


  • Open Access

    Impact of Abdominoperineal Resection on Postoperative Male Sexual Function After Minimally Invasive Rectal Cancer Surgery: A Subgroup Analysis From the LANDMARC Study

    by Taiki Kajiwara, Shinobu Ohnuma, Michiaki Unno, Masakatsu Numata, Tomohiro Yamaguchi, Koya Hida, Tomonori Akagi, Suguru Hasegawa, Akio Shiomi, Ryo Inada, et al.

    Aim: Using data from the LANDMARC study, we aimed to evaluate the impacts of abdominoperineal resection (APR) on postoperative sexual function in males with rectal cancer undergoing minimally invasive surgery. Methods: Patients were categorized into the APR ( n = 44) and anal‐sparing surgery (AS) groups ( n = 329). A detailed subgroup analysis was performed in patients with tumors located < 5 cm from the anal verge (APR, n = 39; AS, n = 59). Sexual function was assessed preoperatively and at 3, 6, and 12 months postoperatively using the International Index of Erectile Function‐5 (IIEF‐5), Erection Hardness Score (EHS), and a customized questionnaire for ejaculatory function. Propensity score–based logistic regression models and longitudinal analyses were applied to address significant baseline imbalances. Results: In the overall cohort, APR was independently associated with significantly impaired erectile function. Adjusted models showed higher predicted probabilities of erectile dysfunction (ErD) after APR at 3 months (38.7% vs. 16.8) and 12 months (34.7% vs. 13.7%). Longitudinal analyses confirmed increased odds of ErD at 3 months (OR 2.86; 95% CI 1.25–6.53) and 12 months (OR 3.05; 95% CI 1.30–7.14). Potency impairment was also significantly more frequent at 3 months. Ejaculatory dysfunction was more common after APR early postoperatively. In patients with tumors located < 5 cm from the anal verge, APR remained associated with impaired erectile function, whereas ejaculatory function showed partial recovery. Conclusion: Results suggest that APR is associated with a high risk of postoperative sexual dysfunction, even in minimally invasive surgery. Sexual function preservation is an important consideration when APR is considered.

  • Open Access

    Data from ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial

    by Takashi Akiyoshi, Eiji Shinozaki, Yusuke Maeda, Senzo Taguchi, Akiko Chino, Yutaka Hanaoka, Shigeo Toda, Shuichiro Matoba, Antony Tin, Erik Spickard, et al.

    Purpose:The role of ctDNA in total neoadjuvant therapy (TNT) and nonoperative management (NOM) for locally advanced rectal cancer (LARC) remains unclear. We evaluated the association of ctDNA with clinical outcomes, including treatment response, local regrowth, and distant recurrence in patients undergoing TNT and NOM.Experimental Design:This biomarker companion analysis of the NOMINATE trial, a prospective, multicenter, randomized phase II study, enrolled 64 patients with T3 to T4NanyM0 LARC between March 2021 and July 2023. Plasma samples (n = 412) were collected at multiple time points: pretreatment (T0), interim evaluations (T1 and T2), final re-staging (T3), and after surgery or after NOM (T4 and beyond). ctDNA was monitored using a tumor-informed multiplex polymerase chain reaction–next generation sequencing assay (Signatera). The association between ctDNA status and clinical outcomes was analyzed.Results:Baseline ctDNA detection was 98.4%, which decreased to 32% at T1, 15% at T2, 30% at T3, and 5% at T4. Among 25 patients achieving clinical complete response (cCR) or near cCR with NOM, ctDNA clearance was 100% at T2 to T4, whereas 39 non-cCR patients showed lower clearance rates (75% at T2 and 51% at T3). ctDNA at T3 had 100% specificity and positive predictive value for pathologic residual disease and was associated with shorter disease-free survival (HR = 6.7, P = 0.005). Local regrowth occurred in five NOM patients, with ctDNA detected in two during surveillance.Conclusions:This study highlights the potential of ctDNA as a predictive and prognostic biomarker in patients with LARC undergoing TNT and subsequently managed by NOM. However, the modest sensitivity of ctDNA highlights the need for technological improvements.See related commentary by Bent et al., p. 5117

  • Open Access

    Table S4 from ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial

    by Takashi Akiyoshi, Eiji Shinozaki, Yusuke Maeda, Senzo Taguchi, Akiko Chino, Yutaka Hanaoka, Shigeo Toda, Shuichiro Matoba, Antony Tin, Erik Spickard, et al.

    Clinical characteristics of patients with local regrowth

  • Open Access

    Table S1 from ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial

    by Takashi Akiyoshi, Eiji Shinozaki, Yusuke Maeda, Senzo Taguchi, Akiko Chino, Yutaka Hanaoka, Shigeo Toda, Shuichiro Matoba, Antony Tin, Erik Spickard, et al.

    Yield of plasma cell-free DNA and circulating tumor DNA detection status in the 412 samples included in this study.

  • Open Access

    Table S2 from ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial

    by Takashi Akiyoshi, Eiji Shinozaki, Yusuke Maeda, Senzo Taguchi, Akiko Chino, Yutaka Hanaoka, Shigeo Toda, Shuichiro Matoba, Antony Tin, Erik Spickard, et al.

    Detailed patient characteristics and the clinical course of each patient.

  • Open Access

    Figure S1 from ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial

    by Takashi Akiyoshi, Eiji Shinozaki, Yusuke Maeda, Senzo Taguchi, Akiko Chino, Yutaka Hanaoka, Shigeo Toda, Shuichiro Matoba, Antony Tin, Erik Spickard, et al.

    Association between circulating tumor DNA levels and pathological characteristics in patients with non-complete response at the final re-staging who underwent surgery

  • Open Access

    Table S3 from ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial

    by Takashi Akiyoshi, Eiji Shinozaki, Yusuke Maeda, Senzo Taguchi, Akiko Chino, Yutaka Hanaoka, Shigeo Toda, Shuichiro Matoba, Antony Tin, Erik Spickard, et al.

    Treatment and pathology outcomes in patients with non-complete response who underwent surgery

  • Open Access

    Short Distal Resection Margin Does Not Increase Recurrence Risk After R0 Resection for Rectal Neuroendocrine Tumors: A Single‐Institution Retrospective Study of 208 Patients

    by Kentaro Sato, Shimpei Matsui, Kaoru Nakano, Yuto Maeda, Tatsuki Noguchi, Takashi Sakamoto, Toshiki Mukai, Tomohiro Yamaguchi, Takashi Akiyoshi

    Aim: The optimal distal resection margin (DRM) for rectal neuroendocrine tumors (NETs) remains unclear. Although rectal NETs are generally considered indolent, aggressive resection may compromise anorectal function. This study aimed to investigate whether shorter DRM affects recurrence risk in patients with rectal NETs undergoing curative resection. Methods: This retrospective study included 208 patients with rectal NETs who underwent total mesorectal excision (TME) at a single institution between January 2005 and December 2023. The patients were categorized into two groups based on DRM length: shorter DRM (SDRM) (≤ 10 mm) and longer DRM (LDRM) (> 10 mm). Clinicopathological characteristics, recurrence patterns, and survival outcomes were compared between the groups. A fine‐grey regression model was used to identify independent predictors of recurrence. Results: Among the 208 patients, 91 (43.8%) had a short DRM. There was no significant difference in the overall recurrence rate between the SDRM and LDRM groups (6.6% vs. 6.0%, p = 1.000), and no local recurrence was reported in either group. In multivariate analysis, tumor size > 20 mm (hazard ratio [HR], 7.01; p = 0.008) and NET G2 (HR, 5.18; p = 0.03) were independent risk factors for recurrence, whereas a short DRM was not. Five‐year overall recurrence and survival rates did not differ between the groups. Conclusions: In rectal NETs, SDRM may not increase the risk of recurrence when R0 resection is achieved. While oncological radicality should remain the highest priority, minimizing DRM may be oncologically safe and could support more function‐preserving surgery, particularly for rectal NET G1/G2.